C4 Therapeutics operates at the forefront of targeted protein degradation with its TORPEDO platform facilitating oral, catalytic, and CNS-penetrant degraders. The company’s lead candidates, cemsidomide for multiple myeloma and CFT8919 for mutant EGFR-driven lung cancer, are advancing clinical stages supported by promising early data and strategic partnerships. Financially, C4 faces persistent operating losses fueled by heavy R&D spends typical of early-stage biotechs, balanced by a robust cash position and collaborations that enhance pipeline breadth. Investors should monitor upcoming Phase 2/1b trial readouts, ongoing development milestones, and regulatory pathways given the novel modality’s uncertainties.